Crosstalk between cytotoxic CD8+ T cells and stressed cardiomyocytes triggers development of interstitial cardiac fibrosis in hypertensive mouse hearts.
CD8+ T cells
NKG2D
RAE-1
STING
TGF-β1
cardiac fibrosis
cardiomyocytes
perforin
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
09
2022
accepted:
31
10
2022
entrez:
9
12
2022
pubmed:
10
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
Cardiac fibrosis is central to heart failure (HF), especially HF with preserved ejection fraction (HFpEF), often caused by hypertension. Despite fibrosis causing diastolic dysfunction and impaired electrical conduction, responsible for arrhythmia-induced sudden cardiac death, the mechanisms are poorly defined and effective therapies are lacking. Here we show that crosstalk between cardiac cytotoxic memory CD8+ T cells and overly stressed cardiomyocytes is essential for development of non-ischemic hypertensive cardiac fibrosis. CD8 T cell depletion in hypertensive mice, strongly attenuated CF, reduced cardiac apoptosis and improved ventricular relaxation. Interaction between cytotoxic memory CD8+ T cells and overly stressed cardiomyocytes is highly dependent on the CD8+ T cells expressing the innate stress-sensing receptor NKG2D and stressed cardiomyocytes expressing the NKG2D activating ligand RAE-1. The interaction between NKG2D and RAE-1 results in CD8+ T cell activation, release of perforin, cardiomyocyte apoptosis, increased numbers of TGF-β1 expressing macrophages and fibrosis. Deleting NKG2D or perforin from CD8+ T cells greatly attenuates these effects. Activation of the cytoplasmic DNA-STING-TBK1-IRF3 signaling pathway in overly stressed cardiomyocytes is responsible for elevating RAE-1 and MCP-1, a macrophage attracting chemokine. Inhibiting STING activation greatly attenuates cardiomyocyte RAE-1 expression, the cardiomyocyte apoptosis, TGF-β1 and fibrosis. Our data highlight a novel pathway by which CD8 T cells contribute to an early triggering mechanism in CF development; preventing CD8+ T cell activation by inhibiting the cardiomyocyte RAE-1-CD8+ T cell-NKG2D axis holds promise for novel therapeutic strategies to limit hypertensive cardiac fibrosis.
Identifiants
pubmed: 36483558
doi: 10.3389/fimmu.2022.1040233
pmc: PMC9724649
doi:
Substances chimiques
Transforming Growth Factor beta1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1040233Informations de copyright
Copyright © 2022 Brassington, Kanellakis, Cao, Toh, Peter, Bobik and Kyaw.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell Rep. 2013 Mar 28;3(3):701-8
pubmed: 23523350
Cell Death Dis. 2021 Mar 26;12(4):322
pubmed: 33771977
Circ Arrhythm Electrophysiol. 2018 Aug;11(8):e006452
pubmed: 30030266
Arterioscler Thromb Vasc Biol. 2018 May;38(5):e71-e84
pubmed: 29599140
Nature. 2018 Jul;559(7713):269-273
pubmed: 29973723
J Biol Chem. 1988 Jun 5;263(16):7741-6
pubmed: 3259578
J Mol Cell Cardiol. 2016 May;94:189-200
pubmed: 26542796
Cell Rep. 2015 Apr 21;11(3):460-73
pubmed: 25865892
Circulation. 2014 May 27;129(21):2111-24
pubmed: 24657994
J Immunol. 2007 Dec 15;179(12):8243-51
pubmed: 18056368
Cancer Res. 2014 Apr 15;74(8):2193-2203
pubmed: 24590060
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4481-4488
pubmed: 30787194
Am J Physiol Heart Circ Physiol. 2010 Nov;299(5):H1328-38
pubmed: 20833959
Circulation. 2013 Mar 5;127(9):1028-39
pubmed: 23395974
Biochem Biophys Res Commun. 2010 Sep 3;399(4):677-82
pubmed: 20691665
PLoS One. 2013 Aug 02;8(8):e72772
pubmed: 23936544
Nature. 1992 May 21;357(6375):247-9
pubmed: 1534146
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4612-E4620
pubmed: 28533362
Clin Immunol Immunopathol. 1995 Dec;77(3):221-8
pubmed: 7586731
J Immunol. 2016 Feb 15;196(4):1822-31
pubmed: 26755819
Nat Rev Drug Discov. 2010 Jan;9(1):57-67
pubmed: 20043028
Hypertension. 1997 Apr;29(4):1025-30
pubmed: 9095094
J Exp Med. 2018 Feb 5;215(2):423-440
pubmed: 29339450
J Immunol. 2014 Apr 1;192(7):3365-73
pubmed: 24600037
Adv Sci (Weinh). 2021 Jan 06;8(5):2002738
pubmed: 33717842
Cell Mol Immunol. 2019 Mar;16(3):236-241
pubmed: 30796349
Nature. 2019 Sep;573(7774):430-433
pubmed: 31511695
Br J Pharmacol. 2010 Aug;160(8):2085-96
pubmed: 20649603
Front Microbiol. 2019 Mar 28;10:630
pubmed: 30984149
J Exp Med. 2017 Nov 6;214(11):3311-3329
pubmed: 28970239
Cardiovasc Res. 2012 Jul 1;95(1):77-85
pubmed: 22492684
Nat Commun. 2015 Sep 25;6:8306
pubmed: 26404698
J Biol Chem. 2013 May 24;288(21):14824-38
pubmed: 23589287
Hypertension. 2002 Jan;39(1):75-80
pubmed: 11799082
PLoS Pathog. 2011 Sep;7(9):e1002265
pubmed: 21966273
Kidney Int. 1995 Oct;48(4):1263-71
pubmed: 8569088
Circ Res. 2014 Jun 20;115(1):79-96
pubmed: 24951759
Circulation. 2004 Aug 10;110(6):705-12
pubmed: 15289376
Immunity. 2019 Dec 17;51(6):1028-1042.e4
pubmed: 31810883
Am J Physiol Heart Circ Physiol. 2020 May 1;318(5):H1139-H1158
pubmed: 32216614
Hypertension. 2001 Sep;38(3 Pt 2):621-4
pubmed: 11566943
Nat Rev Immunol. 2015 Dec;15(12):760-70
pubmed: 26603901
Front Immunol. 2020 Mar 31;11:553
pubmed: 32296442
Curr Opin Cardiol. 2016 Jul;31(4):410-6
pubmed: 27070649
J Hypertens. 2011 Sep;29(9):1820-8
pubmed: 21785365
Am J Transl Res. 2018 Dec 15;10(12):4350-4366
pubmed: 30662677
Biomed Pharmacother. 2020 May;125:110022
pubmed: 32106379
Circulation. 2002 Jul 2;106(1):130-5
pubmed: 12093782
Br Heart J. 1986 Jun;55(6):575-81
pubmed: 3718796
EMBO Mol Med. 2020 Oct 7;12(10):e10865
pubmed: 32955172
Cell Rep. 2021 Mar 2;34(9):108790
pubmed: 33596407
J Mol Cell Cardiol. 2016 Jan;90:84-93
pubmed: 26705059
Biochem Biophys Res Commun. 2003 May 23;305(1):122-8
pubmed: 12732205
Nature. 2009 Sep 10;461(7261):282-6
pubmed: 19741708
Br J Pharmacol. 2013 Sep;170(2):352-65
pubmed: 23750586
Hypertension. 2004 Apr;43(4):739-45
pubmed: 14967845
Exp Mol Med. 2019 Dec 11;51(12):1-9
pubmed: 31827070
Am J Physiol Heart Circ Physiol. 2020 Jun 1;318(6):H1525-H1537
pubmed: 32383996
J Clin Invest. 2017 Oct 2;127(10):3770-3783
pubmed: 28891814
Eur Heart J. 2018 May 21;39(20):1770-1780
pubmed: 29390051
Cell Mol Immunol. 2021 Sep;18(9):2211-2223
pubmed: 32398808
Nature. 2019 Mar;567(7748):394-398
pubmed: 30842653
Biochim Biophys Acta. 2003 Nov 20;1639(3):141-51
pubmed: 14636945
Front Immunol. 2021 Oct 20;12:763647
pubmed: 34745139
Front Immunol. 2018 Nov 15;9:2665
pubmed: 30498501
Annu Rev Immunol. 2014;32:51-82
pubmed: 24313777
Sci Rep. 2021 Jan 12;11(1):617
pubmed: 33436786
Hypertension. 1994 May;23(5):593-9
pubmed: 8175167
J Immunol. 2008 Apr 1;180(7):5036-44
pubmed: 18354229